A Study of KTX-2001 in People With Prostate Cancer

Full Title

Phase 1, Dose-Escalation Study of KTX-2001 (an NSD2 Inhibitor) Alone and in Combination with Darolutamide for Metastatic Castration-Resistant Prostate Cancer

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Wassim Abida’s office at 646-442-4633.

Protocol
26-015
Phase
Phase I (phase 1)
Disease Status
Relapsed or Refractory
Investigator
Wassim Abida
Co-Investigators
Kristine Peregrino Lacuna
Diseases
Genitourinary Cancer › Prostate Cancer
Locations
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Commack Nonna’s Garden Foundation Center
Memorial Sloan Kettering Basking Ridge
Memorial Sloan Kettering Westchester
Memorial Sloan Kettering Monmouth
Memorial Sloan Kettering Bergen
Memorial Sloan Kettering Nassau
ClinicalTrials.gov ID
NCT07103018
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description